Synvisc Articles
Japan approves Genzyme’s Synvisc for osteoarthritis of the knee and grants reimbursement
21 September 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Genzyme manufacturing woes hit sales; Amgen forecasts lower-end of expectations EPS and signs deal with MedGenisis
13 January 2010
Genzyme's 2008 profit down on costs
23 February 2009
FDA panel backs Genzyme's Synvisc-One for OA pain
15 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
Genzyme to set up R&D facility in China
28 April 2008
Genzyme's Synvisc-One awarded EU CE mark
24 December 2007
Genzyme's hylastan falls short in OA trial
16 July 2007
Stock Commentary - New York week to July 9, 2007
16 July 2007
CMS reimbursement cut for osteoarthritis challenged
6 November 2006
New indications OKed for Genzyme's Synvisc
9 October 2006
Stock Commentary - New York week toJune 26, 2006
3 July 2006
Genzyme's 1st-qtr sales less than expected
1 May 2006
Genzyme $57.3M net loss for 4th qtr 2004
28 February 2005
Genzyme completes buyback of Synvisc
17 January 2005
Genzyme posts 1st-qtr net income of $67.9M
26 April 2004
Genzyme files Synvisc in Japan
15 September 2003
Genzyme cutting Canadian jobs
23 February 2001
DTC "set to boost hyaluronic acid in OA"
17 December 1999
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
American Home Pharma Sales Up 7% For 2nd Qtr
22 July 1998
Round-Up Of Products Entering Clinical Trials
27 January 1998
Anika Completes Ph III Orthovisc Trial
4 September 1997
Biomatrix Granted US Approval For Synvisc
18 August 1997
Biomatrix In Synvisc Deal With Bayer
5 May 1997
Performance Still Sought From US Biotech Stocks
21 April 1997
Wyeth-Ayerst Signs Synvisc Deal With Biomatrix
24 February 1997
Biommatrix/Roche Euro deal for Synvisc
4 December 1995
Recordati Sales Boost From Rx Abroad, Italian OTCs
7 August 1995
Synvisc Approved In Sweden
27 March 1995
BIOMATRIX TO DISTRIBUTE SYNVISC
11 July 1994
Showing 1-37 of 37 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
